Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro cell culture and animal injury models with no human data.
What was done
Researchers evaluated the relationship between the pentadecapeptide BPC 157 and vascular endothelial growth factor (VEGF) expression across in vitro cell culture models and in vivo animal injury models (crushed muscle, transected muscle, and transected tendon). Muscle and tendon healing were evaluated through immunohistochemical analysis targeting VEGF, CD34, and factor VIII (FVIII) antibodies.
What was found
BPC 157 showed no direct angiogenic effect in in vitro cell cultures. In vivo, immunohistochemical staining for VEGF, CD34, and FVIII showed modulated angiogenesis and improved muscle and tendon healing in BPC 157-treated animals through VEGF up-regulation. The abstract reports no numerical values, sample sizes, or effect estimates.
Why it matters
The findings suggest that BPC 157 promotes musculoskeletal tissue repair in vivo through secondary angiogenic pathways driven by VEGF modulation rather than a direct cellular angiogenic trigger.
Limits
The study is entirely preclinical with no human subjects. The abstract does not report sample sizes, animal species, control groups, dosage regimens, or quantitative statistical results.
Cited by
- supports BPC-157 is a synthetic version of a naturally occurring gastric peptide that enhances blood vessel growth in areas of injury.